Simulation-based approaches for drug delivery systems: Navigating advancements, opportunities, and challenges

Journal of Molecular Liquids, Journal Year: 2023, Volume and Issue: 395, P. 123888 - 123888

Published: Dec. 27, 2023

Efficient drug delivery systems (DDSs) play a pivotal role in ensuring pharmaceuticals' targeted and effective administration. However, the intricate interplay between formulations poses challenges their design optimization. Simulations have emerged as indispensable tools for comprehending these interactions enhancing DDS performance to address this complexity. This comprehensive review explores latest advancements simulation techniques provides detailed analysis. The encompasses various methodologies, including molecular dynamics (MD), Monte Carlo (MC), finite element analysis (FEA), computational fluid (CFD), density functional theory (DFT), machine learning (ML), dissipative particle (DPD). These are critically examined context of research. article presents illustrative case studies involving liposomal, polymer-based, nano-particulate, implantable DDSs, demonstrating influential simulations optimizing systems. Furthermore, addresses advantages limitations It also identifies future directions research development, such integrating multiple techniques, refining validating models greater accuracy, overcoming limitations, exploring applications personalized medicine innovative DDSs. employing like MD, MC, FEA, CFD, DFT, ML, DPD offer crucial insights into behaviour, aiding Despite advantages, rapid cost-effective screening, require validation addressing limitations. Future should focus on models, enhance outcomes. paper underscores contribution emphasizing providing valuable facilitating development optimization ultimately patient As we continue explore impact advancing discovery improving DDSs is expected be profound.

Language: Английский

---

Quercetin-functionalized nanomaterials: Innovative therapeutic avenues for Alzheimer's disease management

Ageing Research Reviews, Journal Year: 2025, Volume and Issue: unknown, P. 102665 - 102665

Published: Jan. 1, 2025

Language: Английский

---

Caffeic acid loaded into engineered lipid nanoparticles for Alzheimer's disease therapy

Colloids and Surfaces B Biointerfaces, Journal Year: 2023, Volume and Issue: 225, P. 113270 - 113270

Published: March 17, 2023

Alzheimer's disease (AD) is an incurable neurological illness and the leading cause of dementia, characterized by amyloid β (Aβ) fibril deposits. Caffeic acid (CA) has demonstrated potential value for AD therapy due to its anti-amyloidogenic, anti-inflammatory, antioxidant properties. However, chemical instability limited bioavailability limit therapeutic in vivo. Herein, liposomes loading CA were produced distinct techniques. Taking advantage overexpression transferrin (Tf) receptors brain endothelial cells, Tf was conjugated liposomes' surface direct CA-loaded nanoparticles (NPs) blood-brain barrier (BBB). The optimized Tf-modified NPs exhibited a mean size around 140 nm, polydispersity index lower than 0.2, neutral charge, being appropriate drug delivery. Tf-functionalized showed suitable encapsulation efficiency physical stability at least 2 months. Furthermore, simulated physiological settings, ensured sustained release 8 days. anti-amyloidogenic efficacy delivery system (DDS) investigated. data show that are capable preventing Aβ aggregation formation, disaggregating mature fibrils. Hence, proposed brain-targeted DDS may be strategy treating AD. Future studies animal models will valuable validate nanosystem.

Language: Английский

---

Mesenchymal and Neural Stem Cell-Derived Exosomes in Treating Alzheimer’s Disease

Bioengineering, Journal Year: 2023, Volume and Issue: 10(2), P. 253 - 253

Published: Feb. 15, 2023

As the most common form of dementia and a progressive neurodegenerative disorder, Alzheimer’s disease (AD) affects over 10% world population with age 65 older. The is neuropathologically associated loss neurons synapses in specific brain regions, deposition amyloid plaques neurofibrillary tangles, neuroinflammation, blood–brain barrier (BBB) breakdown, mitochondrial dysfunction, oxidative stress. Despite intensive effort, there still no cure for disorder. Stem cell-derived exosomes hold great promise treating various diseases, including AD, as they contain variety anti-apoptotic, anti-inflammatory, antioxidant components. Moreover, stem also promote neurogenesis angiogenesis can repair damaged BBB. In this review, we will first outline major neuropathological features AD; subsequently, discussion cells, cell-secreted exosomes, exosome isolation methods follow. We then summarize recent data involving use mesenchymal cell- or neural AD. Finally, briefly discuss challenges, perspectives, clinical trials using AD therapy.

Language: Английский

---

The modification of conventional liposomes for targeted antimicrobial delivery to treat infectious diseases

Discover Nano, Journal Year: 2025, Volume and Issue: 20(1)

Published: Jan. 30, 2025

Some of the most crucial turning points in treatment strategies for some major infectious diseases including AIDS, malaria, and TB, have been reached with introduction antimicrobials vaccines. Drug resistance poor effectiveness are key limitations that need to be overcome. Conventional liposomes explored as a delivery system bioactives treat provide an efficient approach maximize therapeutic outcomes, drug stability, targetability, reduce side-effects antimicrobials, enhance vaccine performance where necessary. However, pathological understanding become more known, advanced liposomal technologies was born continue having profound effect on targeted chemotherapy diseases. This review therefore provides concise incursion into recent vogue formulations used An appraisal immunological, stimuli-responsive, biomimetic functionalized other novel modifications conventional is assimilated sync mutations resistant pathogens.

Language: Английский

---

Photobiomodulation in Alzheimer’s Disease—A Complementary Method to State-of-the-Art Pharmaceutical Formulations and Nanomedicine?

Pharmaceutics, Journal Year: 2023, Volume and Issue: 15(3), P. 916 - 916

Published: March 11, 2023

Alzheimer’s disease (AD), as a neurodegenerative disorder, usually develops slowly but gradually worsens. It accounts for approximately 70% of dementia cases worldwide, and is recognized by WHO public health priority. Being multifactorial disease, the origins AD are not satisfactorily understood. Despite huge medical expenditures attempts to discover new pharmaceuticals or nanomedicines in recent years, there no cure many successful treatments available. The current review supports introspection on latest scientific results from specialized literature regarding molecular cellular mechanisms brain photobiomodulation, complementary method with implications AD. State-of-the-art pharmaceutical formulations, development nanoscale materials, bionanoformulations applications perspectives highlighted. Another goal this was speed transition completely paradigms multi-target management AD, facilitate remodeling through therapeutic models high-tech light lasers integrative nanomedicine future. In conclusion, insights interdisciplinary approach, including photobiomodulation (PBM) applied human clinical trials, combined drug delivery systems easily overcome protective barriers, could open avenues rejuvenate our central nervous system, most fascinating complex organ. Picosecond transcranial laser stimulation be successfully used cross blood-brain barrier together nanotechnologies, therapy. Original, smart targeted multifunctional solutions nanodrugs may soon developed treat

Language: Английский

---

Transferrin-Conjugated PLGA Nanoparticles for Co-Delivery of Temozolomide and Bortezomib to Glioblastoma Cells

ACS Applied Nano Materials, Journal Year: 2023, Volume and Issue: 6(15), P. 14191 - 14203

Published: Aug. 3, 2023

Glioblastoma (GBM) represents almost half of primary brain tumors, and its standard treatment with the alkylating agent temozolomide (TMZ) is not curative. Treatment failure partially related to intrinsic resistance mechanisms mediated by O6-methylguanine-DNA methyltransferase (MGMT) protein, frequently overexpressed in GBM patients. Clinical trials have shown that anticancer bortezomib (BTZ) can increase TMZ's therapeutic efficacy patients downregulating MGMT expression. However, clinical application this strategy has been stalled due high toxicity combined therapy. The co-delivery TMZ BTZ through nanoparticles (NPs) poly(lactic-co-glycolic acid) (PLGA) proposed work, aiming explore their synergistic effect while decreasing drug's toxicity. developed NPs were optimized central composite design (CCD), then further conjugated transferrin (Tf) enhance targeting ability blood-brain barrier (BBB) cancer cells. obtained exhibited suitable cell delivery features (sizes lower than 200 nm, low polydispersity, negative surface charge) a controlled sustained release for 20 days. uptake antiproliferative evaluated vitro human models. results disclosed are rapidly taken up cells, promoting drug effects inhibiting tumor survival proliferation. This cytotoxicity was associated significant cellular morphological changes. Additionally, biocompatibility unloaded healthy demonstrating safety nanocarrier. These findings prove Tf-conjugated PLGA promising approach treat GBM, overcoming limitations current strategies, such as increased side effects.

Language: Английский

---

Nanotechnology Approaches for Prevention and Treatment of Chemotherapy‐Induced Neurotoxicity, Neuropathy, and Cardiomyopathy in Breast and Ovarian Cancer Survivors

Small, Journal Year: 2023, Volume and Issue: unknown

Published: April 14, 2023

Nanotechnology has emerged as a promising approach for the targeted delivery of therapeutic agents while improving their efficacy and safety. As result, nanomaterial development selective targeting cancers, with possibility treating off-target, detrimental sequelae caused by chemotherapy, is an important area research. Breast ovarian cancer are among most common types in women, chemotherapy essential treatment modality these diseases. However, chemotherapy-induced neurotoxicity, neuropathy, cardiomyopathy side effects that can affect breast survivors quality life. Therefore, there urgent need to develop effective prevention strategies adverse effects. Nanoparticles (NPs) have extreme potential enhancing but require continued research elucidate beneficial interventions women survivors. In short, nanotechnology-based approaches preventing cardiomyopathy. NP-based drug systems therapeutics shown reducing chemotherapeutics efficacy. this article, latest nanotechnology discussed.

Language: Английский

---

Muscle–Brain crosstalk in cognitive impairment

Frontiers in Aging Neuroscience, Journal Year: 2023, Volume and Issue: 15

Published: July 27, 2023

Sarcopenia is an age-related, involuntary loss of skeletal muscle mass and strength. Alzheimer's disease (AD) the most common cause dementia in elderly adults. To date, no effective cures for sarcopenia AD are available. Physical cognitive impairments two major causes disability population, which severely decrease their quality life increase economic burden. Clinically, strongly associated with AD. However, underlying factors this association remain unknown. Mechanistic studies on – brain crosstalk during impairment might shed light new insights novel therapeutic approaches combating decline In review, we summarize latest emphasizing between impairment. The mechanisms involved potential implications such discussed. Finally, future directions drug development to improve age-related AD-related dysfunction also explored.

Language: Английский

---

Harnessing the power of biological macromolecules in hydrogels for controlled drug release in the central nervous system: A review

International Journal of Biological Macromolecules, Journal Year: 2023, Volume and Issue: 254, P. 127708 - 127708

Published: Nov. 1, 2023

Language: Английский

---